Early Efficacy of Clone RMP-14 O of PD-1 antibody inveiled/
A new study demonstrates that ichorbio's RMP1-14 (ICH1132) clone exhibits significant early-stage efficacy and a consistent performance profile in tumor growth inhibition studies compared to the currently established gold standard RMP1-14 clone.
ICH1132 is ichorbio's low endotoxin rat anti-mouse PD-1 antibody
Early-Stage Efficacy
Significant tumor growth inhibition observed on days 14, 17, and 19 in our recent study.
Consistent Performance
Trend towards higher tumor growth inhibition percentages compared to Competitor B.
Lower Endotoxin Levels
ICH1132 (0.013 EU/mg) vs Competitor B (0.056 EU/mg), potentially beneficial for certain research contexts.
Similar Safety Profile
Comparable effects on body weight to Competitor B, indicating similar tolerability.
ICH1132 vs Competitor B: Tumor Growth Inhibition Tumor Volume Over Time
Tumor Growth Inhibition (TGI) Over Time
This graph illustrates the change in tumor volume over time for three groups: the control group (Isotype Control), and two treatment groups (ICH1132 and Competitor B). The y-axis shows the tumor volume in cubic millimeters (mm³), while the x-axis represents the number of days since treatment began. Error bars indicate the standard error of the mean (SEM) for each data point.
This graph illustrates the Tumor Growth Inhibition (TGI) percentage for ICH1132 and Competitor B over the course of the study. The y-axis represents the TGI percentage, where higher values indicate greater tumor growth inhibition relative to the control group. The x-axis shows the number of days since treatment began.
Key Benefits:
Potential for clearer results in early-stage tumor growth studies.
Opportunity to explore the impact of lower endotoxin levels.
Potential for clearer results in early-stage tumor growth studies.